|
The Indian pharmaceutical industry is adopting a pragmatic approach to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), which will be instrumental in ensuring a smooth transition to a more ethical and transparent marketing environment.
UCPMP, introduced in 2024, has evoked good response from the Indian pharmaceutical industry. While some concerns have been raised, the industry has largely adopted a pragmatic approach to its implementation, said Sunil Attavar former president, Karnataka Drugs and Pharmaceutical Manufacturers Association and member, IDMA (Indian Drug Manufacturers Association).
The companies have been actively working to ensure compliance with the UCPMP. This includes updating internal policies and procedures, conducting training programs for employees, and implementing systems to monitor marketing activities.
While the UCPMP has been generally well-received, there have been concerns raised about certain provisions. For instance, some companies have expressed concerns about the impact of restrictions on gifts and benefits on their relationships with healthcare professionals, said a section of sales teams from pharma companies who did not want to be identified.
Voicing concerns of UCPMP, sales teams also noted implementing the UCPMP can be costly, particularly for smaller pharmaceutical companies. This includes the need for training, updating internal systems, and conducting audits to ensure compliance.
Also, UCPMP is a domestic code, and there may be differences between its requirements and global standards for pharmaceutical marketing. This can create challenges for Indian companies that operate in multiple markets, said sales teams.
While challenges may persist, the industry's commitment to compliance and its willingness to engage with regulators suggest that the UCPMP will have a positive impact on the Indian pharmaceutical sector, said Attavar.
The industry has been engaging with regulatory authorities to seek clarification and address concerns. This collaboration has helped to ensure a smooth implementation of the UCPMP and has contributed to a more constructive dialogue between the industry and regulators, said Attavar.
The industry has emphasized the importance of the UCPMP in promoting ethical marketing practices and protecting patient safety. By adhering to the code, Indian pharmaceutical companies are demonstrating their commitment to responsible business practices, Attavar noted.
|